Why Ex Vivo CAR-T Manufacturing Is a Structural Bottleneck
Autologous ex vivo CAR-T manufacturing is the primary barrier to broader clinical access: it requires extracting a patient’s T cells, engineering them outside the body over several weeks, and reinfusing the product — a process that is complex, costly, and time-intensive. The field is now pivoting toward in vivo CAR-T generation strategies, wherein CAR-encoding constructs are delivered directly into the host to reprogram circulating or tissue-resident T cells without any ex vivo culture step.
Two converging problems are driving this shift, as noted in a 2022 review from Huazhong University of Science and Technology: first, the manufacturing complexity of autologous ex vivo CAR-T products; and second, safety concerns around allogeneic approaches, including FDA clinical holds on allogeneic CAR-T programs, which have created urgency for in vivo alternatives that retain autologous T cell identity while bypassing ex vivo culture.
The two principal technological platforms emerging from the retrieved patent and literature dataset are lipid nanoparticle (LNP)-encapsulated mRNA delivery and engineered viral vectors for direct in vivo transduction. Both approaches share a common goal: to convert the patient’s own immune system into a CAR-T manufacturing facility, using the body itself as the bioreactor.
In vivo CAR-T generation refers to the direct delivery of CAR-encoding genetic constructs into a living patient — via lipid nanoparticles, viral vectors, or other carriers — to reprogram the patient’s own circulating or tissue-resident T cells to express chimeric antigen receptors, without removing cells from the body for ex vivo engineering.
A critical molecular pathway underpinning all in vivo CAR-T constructs is the T cell receptor (TCR)/CD3 activation and co-stimulation axis, specifically involving CD28 and 4-1BB (CD137) intracellular signalling domains and the CD3ζ chain — components that appear as universal elements across construct designs in this dataset, regardless of delivery modality.
Allogeneic CAR-T programs have encountered FDA clinical holds, according to a 2022 review from Huazhong University of Science and Technology, creating urgency for in vivo CAR-T generation alternatives that retain autologous T cell identity while bypassing ex vivo culture.
LNP-Delivered mRNA: The Most Drug-Product–Aligned In Vivo CAR-T Platform
LNP-delivered mRNA represents the most clinically tractable in vivo CAR-T platform in the current dataset, because it builds directly on manufacturing processes and safety data validated at scale by COVID-19 vaccines. The landmark proof-of-concept was described in a 2022 commentary from King’s College London covering the Rurik et al. study published in Science: CD5-targeted LNPs carrying modified mRNA encoding an antifibrotic CAR were administered intravenously to mice with cardiac injury, producing transient but functional CAR T cells in vivo that reduced fibrosis and restored cardiac function — a non-oncology application that broadens the potential indication scope of the platform.
“CD4 antibody-conjugated LNPs achieve approximately 30-fold enrichment of reporter mRNA in splenic T cells following systemic injection in mice — a key enabling step toward cell-type-selective in vivo CAR-T programming.”
The Fred Hutchinson Cancer Research Center (Stephan laboratory) has produced two foundational papers on this approach. A 2020 study describes polymer nanocarriers delivering in vitro-transcribed (IVT) CAR or TCR mRNA intravenously to reprogram circulating T cells transiently. In mouse models of human leukemia, prostate cancer, and hepatitis B-associated hepatocellular carcinoma, repeated infusions induced sufficient host T cells expressing tumour-specific CARs or TCRs to cause disease regression comparable to ex vivo–engineered lymphocytes. A companion 2017 paper from the same group describes “hit-and-run” mRNA nanocarriers for T cell programming, demonstrating both CAR delivery and genome-editing cargo delivery.
Cell-type selectivity is the critical engineering challenge for systemic LNP delivery, and a 2021 publication from the University of Pennsylvania’s Perelman School of Medicine directly addresses it. CD4 antibody-conjugated LNPs for selective targeting and mRNA delivery to CD4+ T cells achieved approximately 30-fold enrichment of reporter mRNA in splenic T cells following systemic injection in mice. This work establishes surface receptor-conjugated LNPs as a key enabling technology for in vivo CAR-T, building on the same lipid nanoparticle chemistry validated in clinical siRNA and mRNA therapeutics.
On the patent side, a 2023 Chinese patent filing from West China Hospital, Sichuan University discloses a method for in vivo CAR-T generation using LNPs modified with surface-conjugated antibodies (via thioether coupling chemistry) to encapsulate retroviral vectors carrying the CAR gene, enabling targeted in vivo delivery to T cells. The inventors explicitly position LNP technology — established clinically for siRNA and mRNA delivery — as a platform for intracorporeal CAR-T manufacturing.
A 2021 University of Pennsylvania study demonstrated that CD4 antibody-conjugated lipid nanoparticles (LNPs) achieve approximately 30-fold enrichment of reporter mRNA in splenic T cells following systemic injection in mice, establishing cell-type-selective in vivo T cell targeting as a viable strategy for LNP-based CAR-T programming.
Explore the full patent and literature landscape for LNP-delivered CAR-T constructs in PatSnap Eureka.
Search In Vivo CAR-T Patents in PatSnap Eureka →All LNP-mRNA in vivo CAR-T approaches identified in this dataset remain at the preclinical stage, with evidence from mouse models only. No human clinical data were identified for this specific modality. The Rurik et al. study was explicitly characterised in a retrieved commentary as a proof-of-concept rather than a clinical result. This preclinical status contrasts sharply with the regulatory maturity of the underlying LNP delivery technology itself, which has been validated in millions of human subjects through COVID-19 mRNA vaccines according to data published by WHO.
Viral Vectors for Direct In Vivo T Cell Transduction: AAV, Lentivirus, and Receptor Targeting
Viral vector-based in vivo CAR-T programming encompasses three distinct strategies: AAV-mediated gene delivery, receptor-targeted lentiviral vectors engineered for T cell selectivity, and direct intravenous infusion of replication-incompetent lentiviral particles. Each approach offers a different trade-off between transduction efficiency, integration risk, immune response, and manufacturing complexity.
AAV-Mediated In Vivo CAR Gene Delivery
A 2021 study from Nanjing University describes adeno-associated virus (AAV) vector delivery of CAR genes directly into a humanised tumour mouse model (NCG), generating sufficient in vivo CAR T cells from a single infusion to cause regression of human T cell leukemia. The authors term this approach “AAV delivering CAR gene therapy” (ACG) and note it may bypass the need for lymphodepletion — a significant potential clinical advantage. This is a key proof-of-concept paper for viral-vector in vivo CAR-T programming, though it remains at the preclinical stage.
Receptor-Targeted Lentiviral Vectors
Multiple results address receptor-targeted lentiviral vectors engineered to selectively transduce specific T cell subsets upon systemic administration. A 2019 paper from the German Cancer Consortium (DKTK, Heidelberg) describes CD4- and CD8-targeted lentiviral vectors delivering a CD19-CAR gene selectively to T cell subtypes, with the transduction enhancer Vectofusin-1 significantly improving delivery rates. The choice of target receptor shapes not just delivery efficiency but the quality of the resulting CAR-T product.
A 2023 paper from the Paul-Ehrlich-Institut describes a CD62L-targeted lentiviral vector (62L-LV) that preferentially transduces less differentiated (naïve/stem cell memory) T cells — the subset most associated with durable anti-tumour responses — with transduction rates up to 70% of CD4+ and 50% of CD8+ primary T cells. CD62L (L-selectin) targeting thus represents a quality-by-design principle for in vivo viral vector CAR-T: not only delivering the CAR gene, but delivering it to the most therapeutically potent T cell subset. This principle is consistent with guidance on cell therapy product characterisation published by the European Medicines Agency.
Direct IV Infusion of Replication-Incompetent Lentiviral Particles
A 2022 study from BC Cancer (Canada’s Michael Smith Genome Sciences Centre) directly tested the concept of direct intravenous infusion of replication-incompetent VSV-G lentiviral particles carrying an anti-CD19 CAR-2A-GFP transgene in wild-type mice, demonstrating selective B cell depletion — the expected pharmacodynamic endpoint — in vivo without ex vivo T cell manipulation. This represents the clearest proof-of-concept for direct lentiviral infusion as an in vivo CAR-T programming strategy in the dataset. However, this approach faces significant safety scrutiny around off-target transduction, insertional mutagenesis risk, and anti-vector immune responses, consistent with regulatory frameworks for gene therapy products described by the FDA.
A 2023 paper from the Paul-Ehrlich-Institut demonstrated that a CD62L-targeted lentiviral vector (62L-LV) preferentially transduces less differentiated naïve and stem cell memory T cells — the subset most associated with durable anti-tumour responses — with transduction rates up to 70% of CD4+ and 50% of CD8+ primary T cells.
IP in the direct viral infusion space remains sparse in the retrieved dataset, suggesting early-stage freedom to operate with associated regulatory uncertainty. Ex vivo lentiviral CAR-T products, by contrast, have achieved regulatory approval: third-generation self-inactivating lentiviral vectors have entered multiple clinical trials for CAR-T in B-cell malignancies, leading to the first genetically engineered cell therapy regulatory approvals, including tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta).
Oncolytic Viruses as a Solid Tumour Bridge Strategy for In Vivo CAR-T
Oncolytic virus-based approaches solve a different problem from direct T cell transduction: they use engineered viruses not to reprogram T cells, but to deliver CAR target antigens to tumour cells, converting antigen-negative solid tumours into targets susceptible to pre-existing or co-administered CAR-T cells. This strategy directly addresses the “antigen desert” problem in solid tumours — the lack of tumour-specific surface antigens that can be safely targeted by CARs without on-target/off-tumour toxicity.
A 2020 paper from Stanford University School of Medicine describes a thymidine kinase-disrupted vaccinia virus engineered to deliver CD19 to malignant cells, enabling CD19-CAR T cell activity against two tumour types and improving median survival in an immunocompetent B16 melanoma model. A related 2019 paper from City of Hope National Medical Center describes an oncolytic vaccinia virus expressing truncated CD19 (OV19t) for intratumoral delivery, demonstrating enhanced CAR-T cytokine secretion, cytolysis, and tumour control across multiple mouse tumour models. A 2017 review from the Royal Free London NHS Foundation Trust explicitly frames the oncolytic virus plus CAR-T combination as a solution to the solid tumour antigen desert problem.
Two independent groups — Stanford University and City of Hope — have demonstrated that oncolytic vaccinia virus engineered to express truncated CD19 (OV19t) converts antigen-negative solid tumours into CD19+ targets, enabling attack by pre-existing or co-administered CD19-CAR T cells and improving survival in immunocompetent mouse tumour models. This approach may be closer to clinical translation for solid tumour indications than direct in vivo T cell programming strategies.
This combinatorial approach offers a potentially orthogonal IP and clinical development path for solid tumour indications, where direct in vivo T cell programming faces the additional challenge of intratumoral penetration. The retrieved results show preclinical efficacy across multiple tumour models, and this combination is contextually noted as closer to clinical translation for solid indications than pure in vivo T cell programming strategies.
Map the competitive landscape for oncolytic virus and CAR-T combination patents with PatSnap Eureka.
Explore CAR-T Combination Strategies in PatSnap Eureka →Antigen Targets, Combination CAR Designs, and the IP Whitespace Opportunity
CD19 is the dominant antigen target across retrieved results, serving as the proof-of-concept antigen for in vivo LV infusion, AAV-mediated in vivo CAR delivery, LNP-mRNA approaches, and oncolytic virus platforms. Beyond CD19, the dataset reveals a broad and expanding target landscape: CD20 for tandem targeting to address antigen escape-driven relapse; PD-L1 as both a checkpoint molecule and CAR target; LILRB4 for acute myeloid leukemia; transferrin receptor (TfR); ErbB/HER2 family members; VEGFR2 for tumour vasculature targeting; fibroblast activation protein (FAP) for tumour microenvironment; and HIV envelope glycoprotein (Env) via broadly neutralising antibody-derived scFv domains.
Combination CAR Construct Designs: Checkpoint Blockade Integration
A well-represented patent strategy in the dataset involves integrating checkpoint blockade elements directly into the CAR transgene payload. Multiple patent filings from Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd. — active across JP, KR, and EP jurisdictions — disclose lentiviral CAR-T vectors incorporating PD-L1-blocking scFv, IL-6R-blocking scFv, and IL-6 siRNA within the CAR vector backbone for immune escape suppression and cytokine release syndrome (CRS) mitigation. A 2021 paper from Fudan University describes HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade integrated to overcome exhaustion in chronic infection. This combination design principle — building checkpoint blockade into the CAR construct itself — would be equally applicable to in vivo delivery platforms, according to the dataset’s strategic analysis.
The NKG2D/DAP12 axis extends the in vivo programming concept beyond T cells: Myeloid Therapeutics (Cambridge, MA) describes an NKp44-based chimeric antigen cytotoxic receptor utilising the DAP12 signalling adaptor for mRNA-driven in vivo NK cell engineering, offering a parallel modality to in vivo CAR-T. This broadens the addressable immune cell target space for LNP-based approaches. The scientific basis for such approaches is consistent with research on innate immune cell engineering published by Nature.
The IP Whitespace Opportunity
The patent landscape around in vivo CAR-T generation is underdeveloped compared to ex vivo approaches. The most relevant patents in the retrieved dataset are a pending CN filing from West China Hospital, Sichuan University on LNP-based in vivo CAR-T generation (using antibody-conjugated LNPs encapsulating retroviral vectors carrying the CAR gene), and a pending CN filing from Enti (Suzhou) Biotechnology on NKG2D-CAR T cells co-expressing PD-1/IL-7R chimeric receptors. Commercial patent activity in this space is dominated by ex vivo approaches, with Shanghai UniCAR-Therapy holding the most geographically broad portfolio (JP, KR, EP) for combination CAR construct designs.
The patent landscape for in vivo CAR-T generation methods is underdeveloped compared to ex vivo CAR-T approaches. As of the retrieved dataset, the most relevant in vivo CAR-T generation patents are two pending CN filings: one from West China Hospital, Sichuan University covering LNP-based in vivo CAR-T generation, and one from Enti (Suzhou) Biotechnology covering NKG2D-CAR T cells. This represents an IP whitespace opportunity for organisations that can demonstrate in vivo efficacy and file broad method claims on LNP plus CAR mRNA systemic delivery.
Several emerging design directions from the dataset are worth noting for their translational relevance. Physiologically regulated promoters — such as the WAS gene promoter described in two papers from the University of Granada/GENYO (Spain) — mimic TCR-like expression kinetics in lentiviral vectors, reducing tonic signalling and T cell exhaustion. This principle would be equally critical for any in vivo delivery vehicle to avoid overstimulation of in situ–programmed T cells. Non-integrating approaches including minicircle DNA (mcDNA), episomal nanovectors, and non-integrating lentiviral vectors with S/MAR elements also appear in the dataset as alternatives that retain persistent expression without genomic integration risk — potentially relevant as in vivo safety requirements mature. The regulatory science underpinning these safety considerations is actively developed by bodies including the European Medicines Agency and described in guidelines from WHO.
“The patent landscape around in vivo CAR-T generation is underdeveloped compared to ex vivo approaches — the most relevant patents in this dataset are two pending CN filings, signalling a significant IP whitespace opportunity for organisations that can demonstrate in vivo efficacy.”
For organisations evaluating entry into in vivo CAR-T generation, the dataset’s strategic analysis points to LNP-mRNA as the most drug-product–aligned translation pathway given established clinical safety, scalable manufacturing, and regulatory precedent from COVID-19 vaccines. Developers building on this platform should prioritise T cell-selective targeting ligand chemistry (CD4, CD5, CD62L antibody conjugation) and immunogenicity management of the mRNA cargo. The PatSnap Eureka platform enables systematic mapping of this emerging IP landscape across jurisdictions, helping R&D teams identify whitespace and freedom-to-operate opportunities before the field matures. Additional competitive intelligence resources are available at PatSnap Resources.